Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vagal nerve stimulation using an
NCP
(Cyberonics) device has been suggested as a potential treatment for patients with epilepsy that has previously proven refractory. Ten patients in Northern Ireland have had this device implanted and been fully audited pre- and post-operatively. Twelve months post-implantation, five patients have demonstrated a greater than 50% reduction in
seizure
frequency. A statistical reduction in
seizure
severity of the ictal phase of the major
seizures
has also been shown. Improvement in the patients' overall quality of life has, however, not been demonstrated in parallel to
seizure
reduction.
Seizure
2000 Sep
PMID:Vagal nerve stimulation in patients with refractory epilepsy. Effect on seizure frequency, severity and quality of life. 1098 4
The first clinical attempts at neuromodulation in the form of applying functional electrostimulations started some thirty years ago. Nowadays, it is obvious that the approach to neuromodulation and functional electrostimulation has changed significantly. Neuromodulation tends to affect the disturbed function either by the modulation of neuronal signals or by abolition of dysfunction, preserving the intact central nervous system. The mechanism of activity is connected through direct afferent projections, neurotransmitter modulation and neuronal network regulation. NeuroCybernetic Prosthesis (
NCP
; Cyberonics) is a vagal nerve stimulator consisting of a pulse generator, bipolar VNS lead, programming wand with accompanying software for IBM-compatible computer, a tunneling tool and handheld magnets.
NCP
is placed on the left vagal nerve (middle cervical part). In 1988, Penry JK et al. inserted the first human implant. The Food and Drug Association indicated VNS as add-on therapy for diminishing the number of
seizures
in the adults and adolescents over 12 years of age with partial
seizures
, who are resistant to pharmacological therapy.
...
PMID:[Minimally invasive neurosurgical methods in treatment of pharmacoresistant epilepsy]. 1581 55